Sarah Abdulla
Norwich Radiology Academy,Norfolk and Norwich University Hospital, UK
Title: Progression or pseudo progression? A review of nuclear imaging of post-treatment glioblastoma
Biography
Biography: Sarah Abdulla
Abstract
Glioblastoma is a brain tumour in adults with poor median survival despite multimodality treatment. Efficacy of therapy for glioblastoma is assessed by clinical response and imaging features, mainly on magnetic resonance imaging (MRI). There is a subset of treated patients with imaging features in keeping with “progressive disease” but who then show stabilization or resolution despite no change in their treatment regime. It is thought that the “pseudo progression” is due to non-tumoural factors and incorrect diagnosis could lead to an inappropriate change of effective therapy. Conventional MRI is inadequate for differentiating tumour progression from pseudoprogression and nuclear imaging is increasingly being shown to be more sensitive and specific, especially with the development of new biomarkers such as 11C-methionine (C-Met), O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) and 3,4-dihydrocy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA). This is a review of the current research into radiological assessment of post-treatment GBM with nuclear medicine, specifically differentiating between tumour progression and pseudoprogression.
